Alasdair Milton

Alasdair is a leader in KPMG’s Precision Medicine practice. He has over 20 years experience in strategy consulting and market research specializing in inorganic growth and commercial strategy and portfolio optimization for biopharmaceutical, genomic, diagnostic and health system clients, as well as private investors. Alasdair has also worked with numerous pre-revenue biotechnology companies to help them shape their equity story in preparation for capital raise. As a trained cancer  biologist Alasdair helps clients solve complex business problems that require deep scientific and technical knowledge, and he has worked across multiple therapeutic areas, including CNS, hematology, immunology, infectious disease, metabolic diseases, oncology, respiratory, women’s health, as well as rare and ultra-rare diseases.

A particular focus is in cell and gene therapies across both in vivo and ex vivo approaches and all modalities and therapy areas. Alasdair has supported biopharmaceutical clients across the entire cell and gene ecosystem, from manufacturing strategy, to inorganic growth strategy and commercial due diligence on targets for R&D and business development teams, through to commercial launch support, including distribution, supply chain and pricing. He has also led numerous buy-side commercial due diligence projects for private investors looking to deploy capital in the cell and gene space. He has also authored a thought leadership piece on the challenges in “one-and-done” gene therapies and what these mean for biopharmaceutical companies looking to build a presence in this innovative space.

Precision Medicine Engagement Experience

Example Strategy Projects

• Created a strategic roadmap for a pre-revenue genomics company developing a long-read approach for DNA sequencing for basic research and clinical testing
• Development of equity stories for numerous pre-revenue biotech companies in oncology precision medicine, including those developing ADC & bispecific assets
• Mapped the diagnostics testing landscape across 12 countries for a top 10 biopharma as part of its global CDx launch planning for future targeted oncology assets
• Strategy refresh for an established diagnostics company that had witnessed stagnating growth – developed a turnaround strategy that re-focused the company in its core areas and divested its non-core assets, and the company is currently in the middle of executing this strategy
• Growth strategy for a leading biotech company looking to develop a leading presence in cell and gene therapies across the CNS and immunology disease areas
• Inorganic pipeline strategy for a top 20 global biopharmaceutical company seeking to develop a leading presence in the Acute Myeloid Leukemia market
• Growth strategy for a top 5 biopharma looking to increase its market share in the CAR-T market – assessed strategic options that could shorten the ‘vein-to-vein’ turnaround time and also the possibility of banking patient blood when first diagnosed in order to improve the quality of the final CAR-T product
• In-depth market assessment for a global biotech looking to enter an ultra-orphan disease area – conducted an overall market assessment and an ‘outside in’ diligence on a high priority target

Example Commercial Due Diligence Deals

• For a biopharma client looking to acquire a gene therapy company focused on AAV technologies for hemophilia and neurological diseases
• For a private investor looking to acquire a manufacturer of plasmid DNA, a critical component of cell and gene therapies
• For a diagnostics company assessing a Target with a portfolio of commercial and investigational tests in the immuno-oncology market
• For a diagnostics company assessing a Target focused in brachytherapy and also with an AI-based system for improved cancer detection